BIM-IOL System

The BIM-IOL System is an investigational drug-device combination product in which two non-bioerodible silicone pads containing bimatoprost, a prostaglandin analog approved for topical use, are attached to a hydrophobic acrylic monofocal IOL and implanted in the capsular bag during cataract surgery, with a sponsor-stated design duration of three years. It is not approved in any jurisdiction. The sponsor expects regulation as a drug-led combination product and plans a 505(b)(2) NDA submission in 2028 after two phase 3 trials of the 78 mcg system in approximately 400 participants each.

Current evidence is limited to a nonrandomized first-in-human study in 23 analyzed participants and sponsor-reported topline results of a 104-participant phase 1/2 trial. In both, IOP reductions of 34% to 42% were reported, and 95% to 98% of evaluable participants were free of topical IOP-lowering medication at 12 to 36 months. In the phase 1/2 trial, the timolol control arm, which also underwent cataract surgery, had IOP reductions of 37% at 3 months and 35% at 12 months, so the reported difference is the avoidance of daily eye drops rather than greater IOP lowering. Cataract surgery alone lowered IOP by 16.5% in the OHTS observation group, and no study has compared the system with cataract surgery alone. The first-in-human cohort was single-site, unmasked, registered retrospectively, limited to prior prostaglandin analog responders, and tested doses (75, 150, and 300 μg) other than the phase 3 dose. No peer-reviewed phase 1/2 publication, variance estimates, or noninferiority analyses are available, and the sources differ on phase 1/2 enrollment, pooled versus dose-specific medication-free rates, and the timing of the phase 3 BCDVA co-primary endpoint.

In current practice, prostaglandin analogs are the usual initial medical therapy, with an expected IOP reduction of 25% to 33%, and laser trabeculoplasty is also a first-line option; NICE recommends 360° SLT first for newly diagnosed non-advanced chronic open-angle glaucoma. Adherence limits topical therapy: in a meta-analysis of 47 studies, 44% of patients on prostaglandin analogs were adherent at year 1, and persistence fell from 75% at month 6 to 31% at year 3. For patients with glaucoma and cataract whose IOP is at or near target, the European Glaucoma Society supports phacoemulsification alone or with MIGS. The two approved intracameral implants carry corneal endothelial cell warnings: Durysta is limited to a single implant per eye, and iDose TR may be readministered no more than once per year. The sources describe iDose TR durability differently: the 12-month publication of the GC-010 trial reports noninferiority to timolol at months 6, 9, and 12, while stating that the trial was not prospectively powered for the 6, 9, and 12-month evaluations and that the month 6 and 9 analyses were not prospectively defined, whereas the current iDose TR label states that noninferiority was not demonstrated over the 9 months after month 3. No direct comparison of the BIM-IOL System with topical therapy other than timolol, SLT, MIGS, or intracameral implants has been reported, and no price or budget impact estimate is available.